Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22687589 | 1.00 | LMNA (0.43) | LMNAGAAMAPTRAB9ANPFFR2 | |
| SCHEMBL26946408 | 0.81 | S1PR1 (0.46) | PKM | |
| SCHEMBL20716460 | 0.79 | NPFFR2 (0.42) | LMNAGAANPFFR2ALDH1A1KDR | |
| SCHEMBL20703213 | 0.77 | PKM (0.47) | LMNARAB9APKMALDH1A1MEN1 | |
| SCHEMBL20703212 | 0.77 | PKM (0.47) | LMNARAB9APKMALDH1A1MEN1 | |
| SCHEMBL197395 | 0.74 | NOTUM (0.62) | LMNAGAAMAPTRAB9ANPFFR2 | |
| SCHEMBL20702607 | 0.73 | NOTUM (0.42) | LMNAGAAMAPTRAB9APKM | |
| SCHEMBL20702606 | 0.73 | NOTUM (0.42) | LMNAGAAMAPTRAB9APKM | |
| SCHEMBL20716381 | 0.73 | VNN1 (0.40) | PKMNOTUM | |
| SCHEMBL20716316 | 0.73 | NOTUM (0.42) | LMNAGAAMAPTRAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-15 | — | — | US | disclosed |
| US-11427553-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20200369633-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20200369633-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | US | disclosed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369633-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | LMNA 832/4885GAA 1274/4885MAPT 4154/4885 |
| US-11773070-B2 | Dihydrooxadiazinones | CCND2, DPYD, DHPS | LMNA 873/4885GAA 1153/4885MAPT 4231/4885 |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | CCND2, DPYD, DHPS | LMNA 873/4885GAA 1153/4885MAPT 4231/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | LMNA 832/4885GAA 1274/4885MAPT 4154/4885 |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | LMNA 832/4885GAA 1274/4885MAPT 4154/4885 |
| US-11427553-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | LMNA 832/4885GAA 1274/4885MAPT 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.